Intervention not reported
5‐ASA (3 RCTs; 237 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes 5‐ASA (3 RCTs; 237 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
5‐ASA (8 RCTs; 371 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes 5‐ASA (8 RCTs; 371 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
5‐ASA (9 RCTs; 542 participants) · surgically induced remission in Crohn's disease
The intervention probably leads to lower 5‐ASA (9 RCTs; 542 participants) (moderate certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · people with active UC
It is very uncertain whether antibiotics changes failure to induce clinical response at end of study compared with 5‐ASA (very low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
1 finding from 1 review
Failure to maintain clinical remission at end of study · Patients with quiescent ulcerative colitis
It is very uncertain whether antibiotics changes failure to maintain clinical remission at end of study compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Failure to induce clinical remission at end of study · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease improvement · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · people with active UC
Probiotics showed no clear difference in clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Minor adverse events · people with active UC
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review